Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure
Arteriosclerosis, Thrombosis, and Vascular Biology · 2023-12 · 43 (12) · 2256-2264
DOI: 10.1161/atvbaha.123.319897 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023-12. Verfasst von Dien Ye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands (D.…. Hauptthemen laut MEDLINE: Angiotensinogen, Hypertension. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Blood pressure management involves antihypertensive therapies blocking the renin-angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the so-called RAS escape phenomenon, elicited by the compensatory renin elevation upon RAS blockade. Recently, evidence points toward targeting hepatic AGT (angiotensinogen) as a novel approach to block the RAS pathway that could circumvent the RAS escape phenomenon. Removing AGT, from which all angiotensins originate, should prevent further angiotensin generation, even when renin rises. Furthermore, by making use of a trivalent N -acetylgalactosamine ligand–conjugated small interfering RNA that specifically targets the degradation of hepatocyte-produced mRNAs in a highly potent and specific manner, it may be possible in the future to manage hypertension with therapy that is administered 1 to 2× per year, thereby supporting medication adherence. This review summarizes all current findings on AGT small interfering RNA in preclinical models, making a comparison versus classical RAS blockade with either ACE (angiotensin-converting enzyme) inhibitors or AT1 (angiotensin II type 1) receptor antagonists and AGT suppression with antisense oligonucleotides. It ends with discussing the first-in-human study with AGT small interfering RNA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands (D.Y., E.O.C.-L., A.H.J.D.).
- Alnylam Pharmaceuticals, Cambridge, MA (H.-C.T., I.Z.).
ORCID-Profile: Dien Ye, Edwyn O Cruz-López, Ho-Chou Tu, Ivan Zlatev, A H Jan Danser
Zitieren
APA
Ye, D., Cruz-López, E. O., Tu, H. C., Zlatev, I., & Danser, A. H. J. (2023). Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(12), 2256-2264. https://doi.org/10.1161/atvbaha.123.319897
Vancouver
Ye D, Cruz-López EO, Tu HC, Zlatev I, Danser AHJ. Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(12):2256-2264. doi:10.1161/atvbaha.123.319897
BibTeX
@article{Ye2023,
author = {Ye, Dien and Cruz-López, Edwyn O and Tu, Ho-Chou and Zlatev, Ivan and Danser, A H Jan},
title = {Targeting Angiotensinogen With N -Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2023},
volume = {43},
number = {12},
pages = {2256--2264},
doi = {10.1161/atvbaha.123.319897}
}
EUVIMED